Prot #CDRB436J12301: A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients with Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV6